Why the study?
Although studies indicate uninterrupted anticoagulation is superior during catheter ablation of atrial fibrillation, interrupted anticoagulation is still practiced in many centers due to bleeding concerns.
Does uninterrupted direct oral anticoagulation reduce major adverse cerebro-cardiovascular events compared to interrupted anticoagulation in patients undergoing atrial fibrillation ablation?
Does uninterrupted direct oral anticoagulation reduce major adverse cerebro-cardiovascular events compared to interrupted anticoagulation in patients undergoing atrial fibrillation ablation?
Uninterrupted direct oral anticoagulation during atrial fibrillation ablation reduces silent cerebral events compared to interrupted anticoagulation without increasing bleeding risk.
Supports uninterrupted anticoagulation in AF ablation to reduce silent cerebral events; extends Level 1 evidence confirming equivalent safety.
Background Studies indicate that uninterrupted anticoagulation (UA) is superior to interrupted anticoagulation (IA) in the periprocedural period during catheter ablation of atrial fibrillation. Still IA is followed in many centers considering the bleeding risk. This meta‐analysis compares interrupted and uninterrupted direct oral anticoagulation during catheter ablation of atrial fibrillation. Methods A systematic search into PubMed, EMBASE, and the Cochrane databases was performed and five studies were selected that directly compared IA vs UA before ablation and reported procedural outcomes, embolic, and bleeding events. The primary outcome of the study was major adverse cerebro‐cardiovascular events. Results The meta‐analysis included 840 patients with UA and 938 patients with IA. Median follow‐up was 30 days. Activated clotting time (ACT) before first heparin bolus was significantly longer with UA ( P = .006), whereas mean ACT was similar between the two groups ( P = .19). Total heparin dose needed was significantly higher with IA (mean, ‒1.61; 95% CI, ‒2.67 to ‒0.55; P = .003). Mean procedure time did not vary between groups ( P = .81). Overall complication rates were low, with similar major adverse cerebro‐cardiovascular event ( P = .40) and total bleeding ( P = .55) rates between groups. Silent cerebral events (SCEs) were significantly more frequent with IA (log odds ratio, ‒0.90; 95% CI, ‒1.59 to ‒0.22; P < .01; I 2 , 33%). Rates of major bleeding, minor bleeding, pericardial effusion, cardiac tamponade, and puncture complications were similar between groups. Conclusions UA during atrial fibrillation ablation has similar bleeding event rates, procedural times, and mean ACTs as IA, with fewer SCEs.
No takes yet. Share an insight, caveat, or question.
Basu‐Ray et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: